Teladoc Health, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.5B | $2.6B | $2.6B | $2.4B | $2.0B |
| Cost of revenue | — | — | — | $744.0M | $650.3M |
| Research and development | $277.9M | $307.3M | $348.5M | $333.6M | $311.9M |
| Operating income | -$263.0M | -$1.0B | -$248.6M | -$13.7B | -$265.6M |
| Interest expense | $19.7M | $23.8M | $22.3M | $21.9M | $81.1M |
| Pretax income | -$235.5M | -$993.7M | -$219.6M | -$13.7B | -$384.7M |
| Income tax expense | -$35.2M | $7.6M | $760,000 | -$3.8M | $44.1M |
| Net income | -$200.3M | -$1.0B | -$220.4M | -$13.7B | -$428.8M |
| Balance Sheet | |||||
| Cash and equivalents | $781.1M | $1.3B | $1.1B | $918.2M | $893.5M |
| Current assets | $1.1B | $1.7B | $1.5B | $1.3B | $1.2B |
| Total assets | $2.9B | $3.5B | $4.4B | $4.3B | $17.7B |
| Current liabilities | $404.7M | $941.5M | $420.6M | $399.8M | $331.0M |
| Total liabilities | $1.5B | $2.0B | $2.1B | — | — |
| Stockholders' equity | $1.4B | $1.5B | $2.3B | $2.3B | $16.0B |
| Cash Flow Statement | |||||
| Cash from operations | $294.4M | $293.7M | $350.0M | $189.3M | $194.0M |
| Depreciation and amortization | — | — | — | $256.0M | $204.2M |
| Stock-based compensation | $80.4M | $146.0M | $201.6M | $217.9M | $302.6M |
| Capital expenditure | $8.9M | $10.8M | $11.5M | $16.5M | $8.5M |
| Free cash flow | $285.5M | $282.9M | $338.6M | $172.8M | $185.5M |
| Impairments | $71.8M | $790.0M | $0 | $13.4B | $0 |
Shares outstanding 180.5M · Free float 88.2%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.